Intervention Review

Heparin for pregnant women with acquired or inherited thrombophilias

  1. Mark C Walker1,*,
  2. Sarah E Ferguson2,
  3. Victoria M Allen3

Editorial Group: Cochrane Pregnancy and Childbirth Group

Published Online: 17 FEB 2010

Assessed as up-to-date: 30 JUN 2002

DOI: 10.1002/14651858.CD003580

Database Title

Additional Information

How to Cite

Walker MC, Ferguson SE, Allen VM. Heparin for pregnant women with acquired or inherited thrombophilias. Cochrane Database of Systematic Reviews 2003, Issue 2. Art. No.: CD003580. DOI: 10.1002/14651858.CD003580.

Author Information

  1. 1

    University of Ottawa, Department of Obstetrics and Gynecology, Ottawa, Ontario, Canada

  2. 2

    University of Toronto, Department of Obstetrics and Gynecology, Toronto, Canada

  3. 3

    Dalhousie University, Department of Obstetrics and Gynecology, Halifax, Nova Scotia, Canada

*Mark C Walker, Department of Obstetrics and Gynecology, University of Ottawa, Ottawa, Ontario, K1H 8L6, Canada. mwalker@ohri.ca. mwalker99@hotmail.com.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 17 FEB 2010

SEARCH

ARTICLE TOOLS

View Full Article (HTML) Summary (56K)Standard (161K)Full (163K)
 

Abstract

  1. Top of page
  2. Abstract
  3. Plain language summary
  4. 摘要

Background

Thrombophilias, which are associated with a predisposition to thrombotic events, have been implicated in adverse obstetrical outcomes such as intrauterine growth restriction, stillbirth, severe early onset pre-eclampsia, and placental abruption. Heparin administration in pregnancy may reduce the risk of these events.

Objectives

The objective of this review was to assess the effects of heparin on pregnancy outcomes for women with a thrombophilia.

Search methods

We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (July 2002), MEDLINE, EMBASE, CINAHL, Scidex (via OVID Technologies - July 2002) and reference lists and personal files.

We updated the search of the Cochrane Pregnancy and Childbirth Group's Trials Register on 1 October 2009 and added the results to the awaiting classification section.

Selection criteria

Randomized controlled trials comparing heparin with placebo or no treatment, or randomized controlled trials comparing any two treatments. Quasi randomized studies would be included.

Data collection and analysis

Data would be abstracted from identified studies and recorded on a paper form by two reviewers.

Main results

No studies were included.

Authors' conclusions

There are no completed trials to determine the effects of heparin on pregnancy outcomes for women with a thrombophilia.

[Note: The 17 citations in the awaiting classification section of the review may alter the conclusions of the review once assessed.]

 

Plain language summary

  1. Top of page
  2. Abstract
  3. Plain language summary
  4. 摘要

Heparin for pregnant women with acquired or inherited thrombophilias

No evidence from trials on the effects of heparin on pregnancy outcomes for women with a thrombophilia.

Thrombophilias are a group of disorders where the person's blood is prone to thrombosis (clotting). These blood clots can cause life-threatening complications such as DVT (deep vein thrombosis). Thrombophilia can cause a number of serious complications in pregnancy, such as growth restriction, stillbirth and severe pre-eclampsia. Heparin is an anti-clotting drug which thins the blood. It does not seem to have adverse effects on the baby during pregnancy, and few adverse effects on the pregnant woman. However, the review found no trials on the effects of heparin on pregnancy outcomes for women with a thrombophilia.

 

摘要

  1. Top of page
  2. Abstract
  3. Plain language summary
  4. 摘要

背景

使用肝素(Heparin)治療後天或先天性的易生血栓體質(thrombophilias)孕婦

易生血栓體質的孕婦較容易發生胎兒生長遲滯、死產、嚴重型早發性子癇前症和胎盤早期剝離。使用肝素治療可以預防這些併發症發生。

目標

這篇整理的目的是評估使用肝素來治療易生血栓體質孕婦的效果。

搜尋策略

我們搜尋了Cochrane Pregnancy and Childbirth Group trials register (搜尋到2002年7月)、MEDLINE, EMBASE, CINAHL, Scidex (經由 VID Technologies  搜尋到2002年7月)和所列出的參考文獻及個人檔案。

選擇標準

包含比較使用肝素和安慰劑或不治療的隨機對照實驗，任何兩種治療方法的隨機或準隨機對照實驗。

資料收集與分析

由兩位整理作者將相關文獻資料整理出來並記錄在紙上。

主要結論

沒有任何研究文獻符合標準。

作者結論

沒有任何完整的研究報告有關於使用肝素來治療易生血栓體質孕婦效果的結論。

翻譯人

本摘要由周產期醫學會(Taiwan Society of Perinatology)王鐸聲翻譯。

此翻譯計畫由臺灣國家衛生研究院(National Health Research Institutes, Taiwan)統籌。

總結

目前仍沒有任何關於使用肝素來治療易生血栓體質孕婦效果的研究證明。易生血栓體質是一種容易在體內血液中產生血栓的疾病。這種血栓可能引發一些危及生命的併發症例如深層靜脈栓塞(DVT)。對於孕婦，易生血栓體質可能造成胎兒生長遲滯、死產、和嚴重型子癇前症。肝素是一種抗凝血藥物。它不會對孕婦體內的胎兒產生副作用，對孕婦本身也只有些許副作用。但是整理文獻後卻沒發現關於使用肝素來治療易生血栓體質孕婦的研究報告。

View Full Article (HTML) Summary (56K)Standard (161K)Full (163K)